Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Thomas R Jeffry Evans"'
Autor:
Matthew G. Krebs, Jean-Pierre Delord, Thomas R. Jeffry Evans, Maja De Jonge, Sang-We Kim, Marie Meurer, Sophie Postel-Vinay, Jong-Seok Lee, Helen K. Angell, Vidalba Rocher-Ros, Kassondra Meyer, Mei-Lin Ah-See, Pia Herbolsheimer, Zhongwu Lai, Ana Nunes, Susan M. Domchek
Publikováno v:
Krebs, M G, Delord, J-P, Jeffry Evans, T R, De Jonge, M, Kim, S-W, Meurer, M, Postel-Vinay, S, Lee, J-S, Angell, H K, Rocher-Ros, V, Meyer, K, Ah-See, M-L, Herbolsheimer, P, Lai, Z, Nunes, A & Domchek, S M 2023, ' Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, Basket Study ', Lung Cancer, vol. 180, 107216 . https://doi.org/10.1016/j.lungcan.2023.107216
Lung Cancer, 180:107216. Elsevier Ireland Ltd
Lung Cancer, 180:107216. Elsevier Ireland Ltd
Introduction: Preclinical studies have demonstrated increased efficacy with combined DNA damage response inhibition and immune checkpoint blockade compared with either alone. We assessed olaparib in combination with durvalumab in patients with relaps
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f55b6a72887c16967c05c789e2f26d5
https://doi.org/10.1016/j.lungcan.2023.107216
https://doi.org/10.1016/j.lungcan.2023.107216
Autor:
Rebecca Kristeleit, Ruth Plummer, Robert Jones, Louise Carter, Sarah Blagden, Debashis Sarker, Tobias Arkenau, Thomas R. Jeffry Evans, Sarah Danson, Stefan N. Symeonides, Gareth J. Veal, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji
Publikováno v:
British Journal of Cancer.
Background This was a first-in-human Phase 1/2 open-label dose-escalation study of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737. Methods Patients with advanced solid tumours enrolled in dose-escalation cohorts and received SRA737 monotherapy
Autor:
Hua Guo, Douglas K. Marks, Yvonne M. Saenger, Hanina Hibshoosh, Eileen P. Connolly, Yan Lu, Thomas R. Jeffry Evans, Donian Chyong, John Kucharczyk, Juanita Lopez, Kevin Kalinsky, Rebecca Kristeleit, Robyn D. Gartrell, Pan Kim
Publikováno v:
Cancer Investigation. 39:466-472
Eribulin inhibits microtubule polymerization and suppresses epithelial-mesenchymal transition. Conventional pathology approaches have not identified a precise predictive biomarker for Eribulin. We performed qmIF on pre-treatment tissue from 11 patien
Autor:
Alexandra Sala, James M. Cameron, Cerys A. Jenkins, Hugh Barr, Loren Christie, Justin J. A. Conn, Thomas R. Jeffry Evans, Dean A. Harris, David S. Palmer, Christopher Rinaldi, Ashton G. Theakstone, Matthew J. Baker
Publikováno v:
Cancers; Volume 14; Issue 13; Pages: 3048
Pancreatic cancer claims over 460,000 victims per year. The carbohydrate antigen (CA) 19-9 test is the blood test used for pancreatic cancer’s detection; however, its levels can be raised in symptomatic patients with other non-malignant diseases, o
Autor:
Alexander N. Shoushtari, Neil Steven, Cheryl McAlpine, Jeffrey R. Infante, Revashnee Naidoo, Sarah Stanhope, Ita O’Kelly, Omid Hamid, Victoria K Woodcock, Pippa Corrie, Mark R. Middleton, Emma Leach, Alan Anthoney, Sion Lewis, Jacob Hurst, Avinash Gupta, Antonella Vardeu, Thomas R. Jeffry Evans, Mario Sznol
Publikováno v:
Clinical Cancer Research. 26:5869-5878
Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain and an anti-CD3 T-cell engaging domain, which redirects T cells t
Autor:
Gabriel Tremblay, Bruno Daniele, Peter R. Galle, Carlos F. Lopez, Katherine Dick, Thomas R. Jeffry Evans, Richard A Hubner, Uwe Siebert, Andrew Briggs
Publikováno v:
British Journal of Cancer
Background In the Phase 3 REFLECT trial in patients with unresectable hepatocellular carcinoma (uHCC), the multitargeted tyrosine kinase inhibitor, lenvatinib, was noninferior to sorafenib in the primary outcome of overall survival. Post-hoc review r
Autor:
Yasuhiro Funahashi, Hiroki Ikezawa, Lucjan Wyrwicz, Richard S. Finn, Masatoshi Kudo, Shukui Qin, Min Ren, Thomas R. Jeffry Evans, Ari David Baron, Roger K.C. Ngan, Yukinori Minoshima, Fabio Piscaglia, Ann-Lii Cheng, Masafumi Ikeda, Arndt Vogel, Corina E. Dutcus, Jean-Frédéric Blanc, R. Dairiki, Toshiyuki Tamai, Kwang Hyub Han, Michio Kanekiyo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 17
Purpose: In REFLECT, lenvatinib demonstrated an effect on overall survival (OS) by confirmation of noninferiority to sorafenib in unresectable hepatocellular carcinoma. This analysis assessed correlations between serum or tissue biomarkers and effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e245abccc423a21d39f4cc905212001
https://escholarship.org/uc/item/9fv0c960
https://escholarship.org/uc/item/9fv0c960
Autor:
Takayuki Yoshino, Masafumi Ikeda, Richard S. Finn, Thomas R. Jeffry Evans, Lidong Weng, Kenichi Saito, Kalgi Mody, Toshiyuki Tamai, Costanza Paoletti, Satoru Iwasa
Publikováno v:
Cancer Research. 82:CT523-CT523
Background: Development of primary or secondary resistance to anticancer treatments has been a critical challenge since implementation of immune checkpoint inhibitor (ICI) treatments across multiple cancer subtypes. Preclinical studies have indicated
Autor:
Padmanee Sharma, Han Chang, Ian Chau, Péter Szabó, Dimple Pandya, Ming Lei, Johanna C. Bendell, Thomas R. Jeffry Evans, Zachary Boyd, Patrick A. Ott, Yelena Y. Janjigian, Teresa Sanchez, Christopher T. Harbison, Nathan O. Siemers, Filippo de Braud
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(14)
Purpose:In advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC), there is a need to identify biomarkers of response to therapies, such as immune checkpoint inhibitors.Patients and Methods:In post hoc exploratory analyses from CheckMate
Autor:
Francesc Castro-Giner, Nicola Aceto, Stephanie Anderson, Ilona Krol, Barbara Maria Szczerba, Heidi Lane, Martina Maurer, Thomas R. Jeffry Evans, Marc Engelhardt, Felix Bachmann, Ramona Scherrer, Rebecca Kristeleit, Ruth Plummer, Niamh Coleman, Juanita Lopez, Sofia Gkountela, Suzanne Carreira
Publikováno v:
British journal of cancer, vol. 119, no. 4, pp. 487-491
British Journal of Cancer
British Journal of Cancer
Human glioblastoma (GBM) is a highly aggressive, invasive and hypervascularised malignant brain cancer. Individual circulating tumour cells (CTCs) are sporadically found in GBM patients, yet it is unclear whether multicellular CTC clusters are genera